stockrow
Friday 6 November 2026
Export OSTX’s income statement to Excel — free account
OS Therapies Incorporated
OSTX Healthcare Biotechnology
- EPS
- −5.26%
- Free cash flow
- −134.4%
Quarter to June 2026, against a year earlier
0.96
0.02
−2.04%
Follow OSTX
Alert me
OS Therapies Incorporated (OSTX) P/E ratio
OS Therapies Incorporated has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)